Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05451043 |
Title | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | AHS Cancer Control Alberta |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | CAN |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Cross Cancer Institute | RECRUITING | Edmonton | Alberta | Canada | Details |